克里唑蒂尼
肝细胞癌
医学
肿瘤科
临床试验
内科学
临床实习
肺癌
家庭医学
恶性胸腔积液
作者
Qinglian Chen,Chunfeng Xie,Kun-Liang Feng,Haijun Huang,Cheng-Ming Xiong,Tengjiao Lin,Wenjing Wang,Mian Xu,Xianwei Yang,Chong Zhong
摘要
AIMS: Molecular profiling of hepatocellular carcinoma (HCC) has helped identify actionable genomic alterations that could guide therapeutic decision-making and clinical trial enrollment. However, in clinical practice, next-generation sequencing (NGS) is not extensively used in routine clinical care to identify patients with HCC who are likely to benefit from genome-directed targeted therapies. METHODS: Here, we describe the case of a 66-year-old man with advanced HCC. After rapid progression on transarterial chemoembolization, the tissue sample obtained from biopsy was subjected to NGS to verify whether precision therapy was an option. RESULTS: Our analysis revealed high MET amplification. The patient received crizotinib (250 mg, bid) and showed a remarkable response. CONCLUSIONS: Our case report suggests NGS could help identify patients with high MET amplification in HCC who were likely to benefit from MET inhibitors; moreover, this requires further investigation in clinical trials.
科研通智能强力驱动
Strongly Powered by AbleSci AI